By Sahil Pandey and Christy Santhosh Feb 17 (Reuters) - Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the drug developer's ...

A single dose of the psychedelic drug dimethyltryptamine (DMT), given with psychological support, rapidly reduced depressive ...

Trump administration officials vetoed the FDA's plan to fast-track the review of a psychedelic treatment for severe ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Researchers reported rapid, significant improvement in depression, with the benefits lasting for months after treatment.

"A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, ...

People taking DMT tended to experience significant relief from their depression for up to three months, the researchers found ...

Rapidly expanding support for psychedelic agents in mental health treatment has introduced unique challenges and essential considerations in the design and implementation of informed consent processes ...

Utah combat veterans who have found hope through psychedelic therapy salute proposed research initiative.

A Phase IIa clinical trial finds that a single, brief dose of DMT (from ayahuasca) provides rapid and lasting relief for depression.

Good afternoon, and welcome back to the Health Brief newsletter. I’m coming to you today from the Anthem theater in Washington, D.C., where the pharmaceutical industry is convening to discuss the ...